Literature DB >> 8712715

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).

S Withoff1, S De Jong, E G De Vries, N H Mulder.   

Abstract

Recently, it has been discovered that DNA topoisomerases are the target of many anti-cancer drugs which were already widely used in the clinic. Using the latest molecular biological techniques much has been learned about the function of DNA topoisomerases in normal cells and in cancer cells, and about how anticancer drugs inhibit these enzymes. In this review we present an overview of the function of human type II DNA topoisomerases, how they are inhibited by certain drugs and on how cancer cells may become resistant to these drugs.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8712715

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  10 in total

1.  Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Authors:  Michael F Press; Guido Sauter; Marc Buyse; Leslie Bernstein; Roberta Guzman; Angela Santiago; Ivonne E Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Valerie Bee; Henry Taupin; Kerry J Flom; Isabelle Tabah-Fisch; Giovanni Pauletti; Mary-Ann Lindsay; Alessandro Riva; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene.

Authors:  N Fotouhi-Ardakani; G Batist
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

3.  Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin.

Authors:  Takemitsu Furuchi; Tsutomu Takahashi; Shogo Tanaka; Katsushi Nitta; Akira Naganuma
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

4.  Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Authors:  Michelle Sabourin; John L Nitiss; Karin C Nitiss; Kazuo Tatebayashi; Hideo Ikeda; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

5.  Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.

Authors:  A Gaumann; D S Tews; T Mentzel; P K Petrow; E Mayer; M Otto; C J Kirkpatrick; J Kriegsmann
Journal:  Virchows Arch       Date:  2003-05-13       Impact factor: 4.064

6.  Total synthesis reveals atypical atropisomerism in a small-molecule natural product, tryptorubin A.

Authors:  Solomon H Reisberg; Yang Gao; Allison S Walker; Eric J N Helfrich; Jon Clardy; Phil S Baran
Journal:  Science       Date:  2020-01-02       Impact factor: 47.728

7.  Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

Authors:  A S Betof; Z N Rabbani; M E Hardee; S J Kim; G Broadwater; R C Bentley; S A Snyder; Z Vujaskovic; E Oosterwijk; L N Harris; J K Horton; M W Dewhirst; K L Blackwell
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

8.  High-Copy Overexpression Screening Reveals PDR5 as the Main Doxorubicin Resistance Gene in Yeast.

Authors:  Ayse Banu Demir; Ahmet Koc
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

9.  Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.

Authors:  Xuan Li; Jianguo Dai; Yongjun Tang; Lulu Li; Gang Jin
Journal:  Mar Drugs       Date:  2017-01-18       Impact factor: 5.118

10.  ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells.

Authors:  M Mousli; R Hopfner; A-Q Abbady; D Monté; M Jeanblanc; P Oudet; B Louis; C Bronner
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.